Profiling $KYMR:

I just started investing in this company recently. I don't know the management well yet, but I love their science programs. They are using heterobifunctional degraders like with $ARVN.
1/ Their first indication is IRAK4 in inflammation. This is known to play a big role in inflammation and oncology. They are targeting multiple indications for inflammation.
2/ So far there is only biomarker data, but that is encouraging. The potential of IRAK4 in inflammation could be worth a billion per indication. I think $3 to $5 billion is not unrealistic should it work out as well as hoped.
3/ They are also developing IRAK4+IMID for MYD88 driven cancers. Their lead indication is DLBCL. This is the largest of lymphoma indications. This could be worth up to $750 million sales potential.
4/ Their next set of programs are around STAT3. I have seen a lot of drugs come and go for the JAK/STAT pathway. There are 4 variants of JAK and 6 or 7 with STAT.
5/ They are targeting STAT3 in liquid tumor and fibrotic disorders. There isn't enough information about this program or the patient populations to make any guess about the potential. I do know it could do well over $1 billion if it does well.
6/ Their $3 billion market cap seems extremely expensive for a phase 1 company with just a handful of biomarker data. The expectations are very high with this name. I get the love as I find it the most exciting of the protein degrader companies.
7/ I think valuation should be closer to $2 billion or $40 per share. They need a lot more data on efficacy to show this will be as awesome as we all hope it will be.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Biotech2k

Biotech2k Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Biotech2k1

5 Oct
My game plan updated:

I am still into the buy the dips and sell every rip. I think the collapse in the bubbles in the biotech space are just getting started.
Pathways:

$BPMC 3.36% core position
$TPTX 3.36% core position
$RVMD 2.02% expendable into any big rally
$ERAS 1.34% expendable into any big rally
$RLAY 2.02% expendable into any big rally
Synthetic Lethality:

$MRTX 3.36% core position
$SDGR 2.02% working to pay off core position
$RPTX 2.69% working to pay off core position
Read 7 tweets
4 Oct
Profiling $CABA:

I have been in this company for about 8 months now. I think the management is good, but way too early to tell. They are my small cap high risk play.
1/ They are using CAAR-T to target autoimmune disorders. They use a CAAR receptor that encodes a self antigen that drives auto immune disease. The concept is the self reactive B cells should target binding to the CAAR receptor and the T cell would kill them.
2/ Based on the really low level of memory B cells in the body, it could be very difficult to clear them out. Its a high risk play, but if it works, it could be a huge opportunity.
Read 5 tweets
4 Oct
Profiling $TIL:

This is a newer company that just went off its lock up period. I don't know the management that well, but it can't be any worse than the disastrous $IOVA. That company is completely broken.
1/ They are working on Tumor Infiltrating Lymphocytes (TIL). This is the most successful use of TCR therapies in solid tumors. This starts with removing a met or doing a biopsy of the tumor. It takes that tumor and breaks it down to get all the antigens for that specific patient.
2/ Those tumor antigens are introduced to the patient's own T cells in the lab to activate them toward those antigens. Those T cells are then put back into the patient with PD1 to target and kill all tumor cells and mets.
Read 7 tweets
4 Oct
Profiling $CRBU:

This is a new IPO and they are still within the lock up period until late January. I have followed them as a private company at the ARM conferences as part of my overall CRISPR research for years.
1/ I can safely say I feel this is a good management team at this early stage of the game. They are the original CRISPR company holding all the original patents. They also pioneered new technology with chRDNA.
2/ I classify them as cell therapies because that is where their focus is. They have 3 allogeneic CAR-T programs in development while building an iPSC manufacturing for iNK and iT cells.
Read 9 tweets
3 Oct
Profiling $IPSC:

This is a newer company that recently IPO'd. They are still in the lock up period until mid December. I don't know anything about their management yet. They are working on iPSC cell manufacturing using CRISPR MAD7 editing.
1/ The MAD7 resembles the Cfp1 CAS enzyme. They are focused on developing 2 NK cell programs as their lead programs. They have CNTY-101 which is a standard CD19 and they have CNTY-103 which has CD133.
2/ They are targeting GBM with CNTY-103 which makes this a completely unique program compared to what some other companies are doing. They have some other early CAR-NK and CAR-T programs in development using iPSC.
Read 9 tweets
3 Oct
Profiling $SANA:

I have only been in $SANA for about 6 months, but I really like their 2 franchises. I also like their management team, although, I don't know them that well.
1/ Their first franchise is the Fusogen programs. This is all about delivering any genetic payload to cells. Their fusogen platform uses virus like particles. If we treated this as a stand alone biotech, I would value it around $1 billion to $1.5 billion.
2/ Their second platform is working to build iPSC manufacturing around hypoimmune cells. This will be right along the lines of what $FATE has built. I would also value this platform around $1 billion to $1.5 billion.
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(